...
首页> 外文期刊>Scandinavian journal of gastroenterology. >Introducing a clinical pathway for acute peptic ulcer bleeding in general internal medicine wards.
【24h】

Introducing a clinical pathway for acute peptic ulcer bleeding in general internal medicine wards.

机译:在普通内科病房介绍急性消化性溃疡出血的临床途径。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Management of acute peptic ulcer bleeding (PUB) is expensive and there is little evidence to prove the cost-effectiveness of a clinical pathway. The purpose of this study was to introduce a clinical pathway in hospitalized patients with acute PUB to evaluate its impact on costs and other outcomes. MATERIAL AND METHODS: The clinical pathway was designed for and implemented in hospitalized patients, and a physicians reminder system that included chief residents, checklists, and case review meetings was also utilized. Use of medicine for acid suppression, length of hospital stay (LOS), and treatment costs were compared between patients before and after implementation of the clinical pathway. Outcome measures included the rate of recurrent bleeding, rate of repeat upper gastrointestinal (UGI) endoscopy, and rate of readmission within 30 days of discharge. RESULTS: This clinical pathway significantly reduced the use of intravenous medicine for acid suppression from 88% to 34%, with mean LOS down from 6.7 to 3.6 days, mean cost of medications decreased from New Taiwan Dollars (NTD) 8768 to NTD 3940 (cost down 55.1%), mean cost of diagnostic tests lowered from NTD 12,560 to NTD 9493 (cost down 24.4%), and mean total hospital cost down from NTD 33,142 to NTD 19,519 (cost down 41.1%). Outcome measures were not significantly different. CONCLUSIONS: Introduction of a clinical pathway is an effective method for reducing costs while maintaining quality of care in the management of PUB.
机译:目的:管理急性消化性溃疡出血(PUB)的费用昂贵,而且几乎没有证据证明临床途径的成本效益。这项研究的目的是为住院的急性PUB患者引入临床途径,以评估其对费用和其他结局的影响。材料与方法:该临床途径是为住院患者设计并实施的,还采用了包括主要住院医师,检查表和病例审查会议在内的医生提醒系统。在实施临床途径之前和之后,比较了患者使用抑酸药,住院时间(LOS)和治疗费用。结果指标包括复发出血率,重复上消化道(UGI)内窥镜检查率以及出院30天内再入院率。结果:该临床途径显着减少了静脉内抑制酸的使用,从88%减少到34%,平均LOS从6.7天减少到3.6天,药物的平均费用从新台币(NTD)8768减少到NTD 3940(费用下降55.1%),诊断测试的平均成本从新台币12,560下降到新台币9493(下降24.4%),平均医院总成本从新台币33,142下降到新台币19,519(下降41.1%)。结果指标无显着差异。结论:引入临床途径是在降低成本的同时保持PUB管理中护理质量的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号